Trial Profile
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Dec 2015
Price :
$35
*
At a glance
- Drugs Eleclazine (Primary)
- Indications Arrhythmias; Hypertrophic cardiomyopathy; Ischaemic heart disorders
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 21 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 15 May 2015 New trial record